Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Early Onset SARS-CoV2 Pneumonia
NCT04332042Phase 2Unknown
- Sponsor
- Università Politecnica delle Marche
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in COVID-19 pneumonia, sponsored by Università Politecnica delle Marche. Primary endpoint: Need of mechanical ventilation at 14 days. Status: unknown.
02
Drugs
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04332042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332042.